A Study to Evaluate SHR-1139 Injection in Patients With Pyoderma Gangrenosum

Phase 2 Not yet recruiting 20 enrolled Guangdong Hengrui Pharmaceutical Co., Ltd

NaSingle-groupOpen-labelTreatment

Summary

This study aims to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of SHR-1139 Injection in patients with pyoderma gangrenosum.

Timeline

Start: 2026-03-05
Primary completion: 2027-06
Completion: 2028-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SHR-1139	Unknown	—	—

A Study to Evaluate SHR-1139 Injection in Patients With Pyoderma Gangrenosum

Summary

Timeline

Drugs

Indications